An IRB may suspend or terminate an ongoing clinical study if:
A. Subjects are not being enrolled quickly enough.
B. A drug being used in the trial is approved by FDA.
C. Instructions from the IRB are not being followed.
D. The clinical trial sponsor conducts an audit at the site.